Effect of Chlorhexidine 0.2% in a mucoadhesive polymeric gel from Carbomer and HPC on prevention of ventilator associated pneumonia
Phase 3
- Conditions
- ventilator associated pneumonia.Pneumonia in bacterial diseases classified elsewhereJ17.0
- Registration Number
- IRCT20101211005363N14
- Lead Sponsor
- Zanjan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
Age between 20 to 50 years
Admission less than 24 hours in intensive care unit
Intubated patient
Satisfaction of patients' families
Exclusion Criteria
contraindications to any cause to enteral feeding
pneumonia
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Concentration of polymer in volume. Timepoint: At the beginning of experiment. Method of measurement: By weighing.;The amount of loading of cholorhexidine in gel. Timepoint: At the beginning of experiment. Method of measurement: By weighing.;The amount of release of cholorhexidine in gel. Timepoint: 1,2,3 and 4 hours after gel preparation. Method of measurement: Spectrophotometry.;Ventilator Associated Pneumonia. Timepoint: Third day, Sixth day, Ninth day, The twelfth day. Method of measurement: Clinical Pulmonary Infection Score.
- Secondary Outcome Measures
Name Time Method Mortality rate during hospitalization in Intensive Care Unit. Timepoint: End of the study. Method of measurement: Records.;Connection to ventilator days. Timepoint: End of the study. Method of measurement: Records.;Length of Intensive Care Unit stay. Timepoint: End of the study. Method of measurement: Records.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the mucoadhesive gel's efficacy in preventing ventilator-associated pneumonia?
How does the Carbomer and HPC-based gel compare to standard chlorhexidine solutions in ICU pneumonia prevention?
Are there specific biomarkers that predict response to chlorhexidine-based interventions in VAP prevention?
What are the potential adverse events associated with 0.2% chlorhexidine mucoadhesive gels in critically ill patients?
What combination therapies or alternative antiseptics show promise in preventing ventilator-associated pneumonia compared to chlorhexidine?